Expression of ICAM-1, HLA-DR, and CD80 on peripheral circulating CD1α DCs induced in vivo by IFN-α in patients with chronic hepatitis B

Yong-Sheng Yu, Zheng-Hao Tang, Jing-Chao Han, Min Xi, Jie Feng, Guo-Qing Zang

Abstract

AIM: To explore the effects of interferon-α (IFN-α) application on peripheral circulating CD1α dendritic cells (DCs) in patients with chronic hepatitis B, and the expression of HLA-DR, CD80, and ICAM-1 on CD1α DCs in order to explore the mechanism of immune modulation of IFN-α.

METHODS: By flow cytometry technique, changes of CD1α DCs were monitored in 22 patients with chronic hepatitis B treated with IFN-α and in 16 such patients not treated with IFN-α within three months. Meanwhile, the expression of HLA-DR, CD80, and ICAM-1 on CD1α DCs was detected.

RESULTS: In the group of IFN-α treatment, the percentage of CD1α DCs in peripheral blood mononuclear cells was increased after three months of therapy. In patients who became negative for HBV-DNA after IFN-α treatment, the increase of DCs was more prominent, while in control, these changes were not observed. Increased expression of HLA-DR, CD80, and ICAM-1 on CD1α DCs was also observed.

CONCLUSION: CD1α DCs can be induced by IFN-α in vivo, and the immune related molecules such as HLA-DR, CD80, and ICAM-1 are up-regulated to some degree. This might be an important immune related mechanism of IFN-α treatment for chronic hepatitis B.

© 2006 The WJG Press. All rights reserved.

Key words: Chronic hepatitis B; DC; Immune costimulatory molecules; Immunotherapy; IFN-α
anti-HBV action of IFN-α. The CD1α DC and the expression of ICAM-1, HLA-DR, and CD80 on the cells were determined in the peripheral blood of patients with chronic hepatitis B. Whether DCs can be induced in vivo in patients with chronic hepatitis B treated with IFN-α was investigated. Our study will shed new light on the mechanism of enhanced immune response by IFN-α.

MATERIALS AND METHODS

Subjects
Thirty-eight patients with chronic viral hepatitis B were randomly divided into IFN-α group (n = 22, 16 males, 6 females, aged from 24-48 years, mean 34±6.67) and control group (n = 16, 11 males, 5 females, aged from 25-45 years, mean 35±5.40). Patients were diagnosed with chronic hepatitis B according to the Programme of Prevention and Treatment for Viral Hepatitis revised by Chinese Society of Infectious Disease and Parasitology, Chinese Society of Hepatology, Chinese Medical Association in 2000. Those patients who were diagnosed with chronic hepatitis B were seropositive for HBV markers (HBsAg, HBeAg/anti-HBe, anti-HBc) for more than 6 months, characterized by an intermittent pattern of disease activity with elevations of alanine aminotransferase (ALT) values preceded, and in most instances, by an increase of HBV-DNA levels. The enrolled patients were diagnosed with chronic hepatitis B, in whom serum markers of HBV (HBsAg, HBeAg, HBeAb, HBV-DNA) were positive, ALT level between two and five times normal limit, total bilirubin below two times normal limit, who could bear treatment with IFN-α. Patients who were infected by other virus and diagnosed with autoimmune disease were excluded.

Treatment procedures and reagents
Patients in IFN-α group were treated with 5.0 million units IFN-α daily for 15 d and then every other day for an additional (85) d. The control group was not treated with IFN-α (P  < 0.05). In IFN-α group, the percentage of CD1α DCs was increased. There were significant differences between pre- and post-therapy (p < 0.05). In control group, the percentage of CD1α DCs post-therapy was close to that post-therapy (p > 0.05). In IFN-α group, the percentage of CD1α DCs in the group with decreased HBV-DNA was more than that in the group with HBV-DNA not decreased (p < 0.05) (Table 1).

RESULTS

CD1αDC in peripheral blood with chronic hepatitis B and effect of IFN-α on DCs

The results showed that CD1α DCs existed in peripheral blood of patients with active chronic hepatitis B, and most of them was less than 1% of PBMCs. In IFN-α group, after treatment for three months, the percentage of CD1α DCs in PBMC in some patients was increased. There were significant differences between pre- and post-therapy with IFN-α (P < 0.05). In control group, the percentage of CD1α DCs post-therapy was close to that post-therapy (p > 0.05). In IFN-α group, the percentage of CD1α DCs in the group with decreased HBV-DNA was more than that in the group with HBV-DNA not decreased (p < 0.05) (Table 1).

Effects of IFN-α on the expression of ICAM-1, HLA-DR, and CD80 on surface of CD1αDC

It showed that ICAM-1, HLA-DR, and CD80 on surface of CD1α DC in peripheral blood of patients with active chronic hepatitis B also existed to some extent. Among them, the expression of ICAM-1, HLA-DR was stronger than that of CD80. After treatment with IFN-α for three months, the expression of ICAM-1, HLA-DR, and CD80...
on surface of CD1 α DC was increased to some extent. In IFN-α group, the percentage of ICAM-1, CD80, and HLA-DR on CD1αin peripheral blood after treatment with IFN-α for three months was more than that before treatment. There were significant differences between pre- and post-therapy with IFN-α (P<0.05). In control group, there were no significant differences between pre- and post-therapy (P>0.05) (Table 2).

**DISCUSSION**

Currently, IFN-α is frequently chosen in treatment of chronic hepatitis B[16], but only 30%-40% of treated patients show response to it. How to improve the efficacy of IFN-α is a challenge. IFN-α is involved in immune modulation besides direct anti-HBV effect. The defect in specific T cell immunity, especially HBV-specific cytotoxic T lymphocyte (CTL) dysfunction has long been assumed to be a central mechanism for hepatitis B virus persistent infection. The cause that effective specific T cell immunity is not induced in patients with chronic hepatitis B is not completely clear. DCs are the most potent antigen-presenting cells that initiate protective T-cell immunity. Recent studies in transgenic mice have suggested, however, that functional deficit of DCs is an underlying cause for T cell dysfunction. Studies showed that HBsAg presentation by cytokine-activated DCs can break tolerance and trigger an anti-viral CTL response in HBV transgenic mice[13]. In chronic hepatitis B, DCs are present to some degree in peripheral blood and in the liver tissue and might be involved in the immunopathogenesis of chronic liver diseases[25]. The current results showed that CD1 α DCs existed in peripheral blood in patients with active chronic hepatitis B, and most of them was less than 1% of PBMC. Whether the immune function of these DCs is effective in patients with chronic hepatitis B needs to be studied.

In literature, the reports on whether IFN-α is involved in immune modulation through DCs in treatment of chronic hepatitis B are few. DCs are most powerful to induce immune response among antigen presenting cells in vitro[7,9]. In recent years, more attentions have been paid to the relation between DCs and hepatitis B. DCs sensitized with HBsAg in vitro enhanced the proliferation response of T cell from chronic hepatitis B patients, and successfully induced MHC-I restricted HBV-specific CTLs in mice[14]. These suggest that DCs have powerful ability to present HBsAg. HBV-specific CTLs could be induced in HBV transgenic mice treated with sensitized DCs, therefore, the immune tolerance state of HBV transgenic mice would be broken[14]. It was reported that degree of activation of DC following vaccination would possibly help to predict the outcome of vaccine therapy in HBV carriers[17,18]. All above suggest that DCs play a role in inducing effective immune response to HBV.

However, recent studies have suggested that functional deficit of DCs is an underlying cause for T cell dysfunction. In hepatitis B, not only the numbers of DC subsets were decreased, but also the function of these DCs was impaired in peripheral blood[9-13]. DCs in liver from murine hepatitis B carriers also showed impaired functional capacities[19]. Therefore, to increase the number of and improve the function of DCs is important in patients with chronic HBV infection. DCs could be induced by many kinds of cytokines such as GM-CSF, IL-4 in vitro, and the expression of immune costimulatory molecules can be also up-regulated[20]. Most of studies on DCs in hepatitis B were done through incubation of PBMCs in vitro. In the process, some cytokines were added in order that DCs were induced. So the results observed in vitro could not reflect truly the condition of DCs in vivo. Whether DCs can be induced in vivo in patients with chronic hepatitis B treated with IFN-α was investigated in the current study in an effort to explore the mechanism of enhanced immune response through DCs of IFN-α treatment. In order to observe the changes of peripheral circulating CD1α+DCs and the expression of ICAM-1, HLA-DR, and CD80 on CD1 α DCs in vivo by IFN-α application, flow cytometry technique was employed to detect directly CD1α+DCs.

In our study, the effects of IFN-α on CD1α+DCs were investigated. The results showed IFN-α could up-regulate the percentage of CD1α+DCs in PBMCs besides its direct anti-HBV action. Our findings that the number of CD1α+DCs rose in peripheral blood of patients treated with IFN-α suggested that IFN-α can induce DCs in vivo. Previous studies argued that DCs were lack in patients with chronic hepatitis B, and that immune activity was weak. IFN-α could enhance specific immune response to HBV through inducing DCs in vivo, consequently, facilitating antigen presentation of HBV and specific T cell triggering.

Previous studies suggested that DCs from patients with chronic hepatitis B showed significantly lower expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86) and impaired allostimulatory mixed lymphocyte reaction, as well as decreased number compared with normal group[10,18]. It indicates that the immune response to HBV is enhanced by up-regulating the immune associated molecules on DCs in patients with chronic hepatitis B. Recent studies showed that IFN-α had similar action in vitro. IFN-α is partially involved in immune modulation by inducing DCs in vitro[9]. In our study, the expression

**Table 2 Effects of IFN-α on immune related molecules on CD1 α DC in peripheral blood of patients pre- and post-therapy**

| Group | n | Pre-ICAM-1 | Post-ICAM-1 | Pre-CD80 | Post-CD80 |
|-------|---|------------|-------------|----------|-----------|
| IFN-α | 22 | 54.92±5.95% | 50.61±5.72% | 44.84±9.14% | 40.50±9.47% |
| Control | 16 | 60.17±4.83% | 59.60±4.83% | 45.01±9.08% | 43.42±11.58% |

**Control**

| Group | n | Pre-HLA-DR | Post-HLA-DR | Pre-CD80 | Post-CD80 |
|-------|---|------------|-------------|----------|-----------|
| IFN-α | 22 | 57.86±7.76% | 53.98±7.76% | 33.97±8.37% | 34.80±6.01% |
| Control | 16 | 40.50±9.47% | 43.41±8.13% | 33.42±11.58% | 34.80±6.01% |

<ref>P<0.05 vs pre-therapy.</ref>
of ICAM-1, HLA-DR, and CD80 on surface of CD14+ DCs differently increased in IFN-α group, but there was no significant change in control group. It suggests that IFN-α played some role in up-regulating the expression of ICAM-1, HLA-DR, and CD80. Many immune molecules are involved in triggering T lymphocyte cells by DCs, especially MHC-II, B7-1 (CD80), B7-2 (CD86), ICAM-1, LFA-3, etc. MHC molecules combined with antigen peptides provide first signal for the activation of T lymphocyte cells. The costimulatory molecules (B7-1, B7-2) are important to trigger T lymphocyte cells. The lowered expression of those immune molecules impaires DCs to trigger T lymphocyte cells. During the treatment of IFN-α for patients with chronic hepatitis B, the ability of DCs presenting HBV antigen was differently improved. Our results suggest that IFN-α improves the presenting ability of DCs to some degree, and strenthes the interaction of DCs and T lymphocyte cells through up-regulating the expression of ICAM-1, HLA-DR, and CD80. IFN-α up-regulating the expression of immune molecules on DCs might be an important mechanism of immune modulation in anti-HBV treatment for patients with chronic hepatitis B.

However, the correlation between the efficacy of IFN-α and DCs is still unclear. Although in patients with chronic hepatitis B, peripheral circulating DCs and their expression of ICAM-1, HLA-DR, CD80 are increased by IFN-zaplication, only a minority of treated patients show response to IFN-α. It indicates that the effects of anti-HBV treatment of IFN-α are affected by many other factors[29-31], for example, CD80-B7 interaction promotes immune response, and CD80-CTLA4 interaction down-regulates the response. The function of DC might be affected by these factors, as well[29-31].

REFERENCES

1. Della Bella S, Gennaro M, Vaccari M, Ferraris C, Nicola S, Riva A, Clerici M, Greco M, Villa ML. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 2003; 89: 1463-1472.
2. Murakami H, Akbar SM, Matsui H, Horiike N, Onji M. Decreased interferon-alpha production and impaired T helper 1 polarization by dendritic cells from patients with chronic hepatitis C. Clin Exp Immunol 2004; 137: 559-565.
3. Wang QC, Feng ZH, Zhou YX, Nie QH. Induction of hepatitis C virus-specific cytotoxic T and B cell responses by dendritic cells expressing a modified antigen targeting receptor. World J Gastroenterol 2005; 11: 557-560.
4. Stober D, Treboujaca Z, Reimann J, Schirmeck R. Dendritic cells pulsed with exogenous hepatitis B surface antigen particles efficiently present epitopes to HMC class I-restricted cytotoxic T cells. Eur J Immunol 2002; 32: 1099-1108.
5. Akbar SM, Horiike N, Onji M, Hino O. Dendritic cells and chronic hepatitis virus carriers. Interireology 2001; 44: 199-208.
6. Wang FS, Xing LH, Liu MX, Zhu CL, Liu HG, Wang HF, Lei ZY. Dysfunction of peripheral blood dendritic cells from patients with chronic hepatitis B virus infection. World J Gastroenterol 2001; 7: 537-541.
7. Paillot R, Laval F, Audonnet JC, Andreoni C, Juillard V. Functional and phenotypic characterization of distinct porcine dendritic cells derived from peripheral blood monocytes. Immunology 2001; 102: 396-404.
8. Demir G, Klein HO, Tuzuner N. Low dose daily rhGM-CSF application activates monocytes and dendritic cells in vivo. Leuk Res 2003; 27: 1105-1108.
9. Tosi D, Valenti R, Cova A, Sovena G, Huber V, Pilla L, Arienti F, Belardelli F, Parmigiani G, Rivoltini L. Role of cross-talk between IFN-α-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens. J Immunol 2004; 172: 5327-5337.
10. Senturk H, Tabak F, Akdogan M, Erdem L, Mert A, Ozaras R, Sander E, Ozbay G, Badur S. Therapeutic vaccination in chronic hepatitis B. J Gastroenterol Hepatol 2002; 17: 72-76.
11. Shimizu Y, Guidotti LG, Fowler P, Chisari FV. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J Immunol 1998; 161: 4520-4529.
12. Kurose K, Akbar SM, Yamamoto K, Onji M. Production of antibody to hepatitis B surface antigen (anti-HBs) by murine hepatitis B virus carriers: neonatal tolerance versus antigen presentation by dendritic cells. Immunology 1997; 92: 494-500.
13. Tanimoto K, Akbar SM, Michitaka K, Horiike N, Onji M. Antigen-presenting cells at the liver tissue in patients with chronic viral liver diseases: CD83-positive mature dendritic cells at the vicinity of focal and confluent necrosis. Hepatol Res 2001; 21: 117-125.
14. Horiike N, Md Faze Akbar S, Ninomiya T, Abe M, Michitaka K, Onji M. Activation and maturation of antigen-presenting dendritic cells during vaccine therapy in patients with chronic hepatitis due to hepatitis B virus. Hepatol Res 2002; 23: 38-47.
15. Kunitani H, Shimizu Y, Murata H, Higuchi K, Watanabe A. Phenotypic analysis of circulating and intrahepatic dendritic cell subsets in patients with chronic liver diseases. J Hepatol 2002; 36: 734-741.
16. Dhdapak MV, Steinman RM, Sapp M, Desai H, Fossella C, Krasovsky J, Donahoe SM, Dunbar PR, Cerundolo V, Nixon DF, Bhardwaj N. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999; 104: 173-180.
17. Akbar SK, Horiike N, Onji M. Prognostic importance of antigen-presenting dendritic cells during vaccine therapy in a murine hepatitis B virus carrier. Immunology 1999; 96: 98-108.
18. Fazle Akbar SM, Furukawa S, Onji M, Murata Y, Niya T, Kanno S, Murakami H, Horiike N. Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteers. Hepatol Res 2004; 29: 136-141.
19. Kakumoto S, Itso S, Ishikawa T, Mita Y, Tagaya T, Fukuzawa Y, Yoshioka K. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol 2000; 15: 431-436.
20. Wertheimer AM, Bakke A, Rosen HK. Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. Hepatology 2004; 40: 335-345.
21. van der Molen RG, Sprangers D, Binda RS, de Jong EC, Niesters HG, Kusters JG, Kwakkeboom J, Janssen HL. Functional impairment of myeloid and plasmacytoid dendritic cells in human volunteers. Hepatol Res 2004; 29: 136-141.
22. Duan XZ, Wang M, Li HW, Zhuang H, Xu D, Wang FS. Decreased frequency and function of circulating plasmacytoid dendritic cells (pDC) in hepatitis B virus infected humans. J Immunol 2004; 217: 637-646.
23. Duan XZ, Zhuang H, Wang M, Li HW, Liu JC, Wang FS. Decreased numbers and impaired function of circulating dendritic cell subsets in patients with chronic hepatitis B infection (R2). J Gastroenterol Hepatol 2005; 20: 234-242.
24. Lohr HF, Pingel S, Bocher WO, Bernhard H, Herzog-Hauf S, Rose-John S, Galle PR. Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B – restoration by exogenous interleukin-12. Clin Exp Immunol 2002; 130: 107-114.
25. Hasebe A, Akbar SM, Furuikawa S, Horiike N, Onji M. Impaired functional capacities of liver dendritic cells from murine hepatitis B virus (HBV) carriers: relevance to low HBV-specific immune responses. Clin Exp Immunol 2005; 139: 35-42.
26. Zheng BJ, Zhou J, Qu D, Siu KL, Lam TW, Lo HY, Lee SS, Wen YM. Selective functional deficit in dendritic cell – T cell interaction is a crucial mechanism in chronic hepatitis B virus infection. J Viral Hepat 2004; 11: 217-224.
Dauer M, Pohl K, Obermaier B, Meskendahl T, Robe J, Schnurr M, Endres S, Eigler A. Interferon-alpha disables dendritic cell precursors: dendritic cells derived from interferon-alpha-treated monocytes are defective in maturation and T-cell stimulation. *Immunology* 2003; 110: 38-47

Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. *Cancer Res* 2000; 60: 2444-2448

Zheng P, Wu Y, Guo Y, Lee C, Liu Y. B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge. *Proc Natl Acad Sci USA* 1998; 95: 6284-6289